⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APGE News
Apogee Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
APGE
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
globenewswire.com
APGE
Form 8-K
sec.gov
APGE
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
globenewswire.com
APGE
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
globenewswire.com
APGE
Form 8-K
sec.gov
APGE
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
globenewswire.com
APGE
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
globenewswire.com
APGE
Form 8-K
sec.gov
APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
globenewswire.com
APGE